7th B2B Uro-Oncology: GU Cancers Triad Meeting - KIDNEY CANCER

Friday, October 31, 2025

12:45 - 14:25 GMT+0

Co-Chair(s)

B2B Scientific Programme Committee: Peter Black, Canada / Caroline Moore, United Kingdom / Simon Tanguay, Canada

At the end of this session, attendees should be able to:

Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
Recognize the role of imaging and genetic markers in guiding treatment decision-making.
Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

12:45 - 13:00 GMT+0

SOA: IO Rechallenge After Adjuvant IO
13:00 - 13:15 GMT+0

SOA: Cytoreductive Nephrectomy in the Era of IO
13:15 GMT+0

Debate: Should Oligometastatic RCC Be Treated by Surgery or SBRT?
Moderator: Simon Tanguay – McGill University
13:15 - 13:23 GMT+0

Surgery
13:23 - 13:31 GMT+0

SBRT
13:31 - 13:40 GMT+0

Discussion and Q&A
Moderator: Simon Tanguay – McGill University
13:40 - 14:10 GMT+0

Panel Discussion: Systemic therapy combination in metastatic RCC
Panelist: Christian Kollmannsberger – BC Cancer Vancouver / University of British Columbia
Moderator: Simon Tanguay – McGill University
Panelist: Karima Oualla – Hassan II University Hospital
14:10 - 14:25 GMT+0

SOA: Belzutifan in Metastatic Clear Cell RCC
Speaker: Christian Kollmannsberger – BC Cancer Vancouver / University of British Columbia